市場調査レポート

経肺ドラッグデリバリー市場の機会と臨床パイプライン分析

Pulmonary Drug Delivery Market & Clinical Pipeline Insight

発行 KuicK Research 商品コード 302585
出版日 ページ情報 英文 890 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
経肺ドラッグデリバリー市場の機会と臨床パイプライン分析 Pulmonary Drug Delivery Market & Clinical Pipeline Insight
出版日: 2014年05月01日 ページ情報: 英文 890 Pages
概要

経肺ドラッグデリバリーシステムは、気道を用いて薬剤を肺に送り込むもので、喘息やCOPD、嚢胞性線維症などの疾患の治療に役立てられます。同市場には製薬会社各社が新たな治療法開発のため多くの投資を行なっています。COPDや喘息などの気道関連疾患の発症率の上昇と、ドラッグデリバリー技術における進歩によって、世界の経肺ドラッグデリバリーシステム市場は急速に拡大するものとみられています。

当レポートでは、経肺ドラッグデリバリー市場の概要、市場促進因子と課題、治験動向などとともに、参入する企業の競合環境をまとめ、概略下記の構成で取り上げております。

第1章 経肺ドラッグデリバリーのイントロダクション

第2章 経肺ドラッグデリバリーのメカニズム

  • 経肺ドラッグデリバリーシステムのセグメント
  • ドラッグデリバリーのメカニズム

第3章 なぜ経肺ドラッグデリバリーが必要なのか

第4章 経肺ドラッグデリバリー市場見通し

  • 市場概要
  • 臨床パイプライン分析

第5章 経肺ドラッグデリバリー市場動向

  • 市場促進因子
  • 議論すべき課題

第6章 将来の経肺ドラッグデリバリー市場

第7章 相、国、標的適応別治験動向

第8章 上市済み薬剤プロファイル

第9章 中断、中止された薬剤プロファイル

第10章 競合環境

  • Allergan Inc.
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • Boehringer Ingelheim
  • Gilead Sciences
  • Merck & Co
  • Teva Pharmaceutical
  • Novartis
  • Pfizer
  • Vectura Group

図表

目次

The demand for new and innovative drug delivery systems has been on a rising trend with the pharmaceutical companies concentrating on developing innovative methods for this area. It is the result of these continued efforts, which have led to the ever rising popularity of pulmonary drug delivery methods across the globe. Pulmonary drug delivery system uses the respiratory tract to deliver drugs into the lungs in order to treat diseases such as asthma, COPD and cystic fibrosis. This market has been attracting significant investments by the pharma companies with relation to development of novel treatment methods.

The system of targeted drug delivery to the lungs has become one of the most popularly investigated systemic or local drug delivery approach. With the passing of time, the drug delivery systems specifically being used for the treatment of pulmonary diseases have increased due to their potential for localized topical therapy in the lungs. One of the major advantages offered by this route is that it is possible to deposit drugs more specifically at the site with high concentrations within the diseased lung. This helps in reducing the overall amount of drug given to patients, and also increases local drug activity while simultaneously reducing systemic the side effects and first-pass metabolism.

The pulmonary technology offers an exclusive and inventive alternative for drug delivery as it allows for a systemic delivery of large and small molecule drugs through inhalation into the lungs. This mode of drug delivery have helped in reducing the adverse effects of low solubility and absorption of drugs which are present in the other therapies through the oral, intravenous and injection routes.

Owing to the rising incidences of respiratory tract related diseases like chronic obstructive pulmonary disease (COPD), asthma etc, coupled with the advancements made in the technology of drug delivery, the global market for pulmonary drug delivery system is likely to grow at a rapid rate. Additionally, the pharma companies have recently recognized the future potential of inhaled therapies and the extended application beyond asthma and COPD, and therefore, have been working towards tapping the opportunities for growth through product differentiation.

"Pulmonary Drug Delivery Market & Clinical Pipeline Analysis" Report Highlights:

  • Pulmonary Drug Delivery Market Overview
  • Favorable Market Drivers & Key Issues to be Discussed
  • Pulmonary Drug Clinical Pipeline by Phase, Disease & Country
  • Pulmonary Drug Profiles in Report: 566
  • Majority of Pulmonary Drugs in Preclinical Phase: 79
  • Number of Marketed Pulmonary Drugs: 63
  • Number of Discontinued & Suspended Drug Profiles: 283

Table of Contents

1. Introduction to Pulmonary Drug Delivery

2. Pulmonary Drug Delivery Mechanism

  • 2.1. Segments of Pulmonary Drug Delivery System
  • 2.2. Mechanisms of Drug Delivery

3. Why Need for Pulmonary Drug Delivery?

4. Pulmonary Drug Delivery Market Outlook

  • 4.1. Market Overview
  • 4.2. Clinical Pipeline Analysis

5. Pulmonary Drug Delivery Market Dynamics

  • 5.1. Favorable Market Drivers
  • 5.2. Key Issues to be Discussed

6. Future of Pulmonary Drug Delivery Market

7. Pulmonary Drug Clinical Insight by Phase, Country & Target Indication

  • 7.1. Unknown Phase
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Clinical
  • 7.5. Phase I
  • 7.6. Phase I/II
  • 7.7. Phase II
  • 7.8. Phase II/III
  • 7.9. Phase III
  • 7.10. Preregistration
  • 7.11. Registered

8. Marketed Pulmonary Drug Profiles

9. Suspended & Discontinued Pulmonary Drug Profiles

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Market Withdrawal
  • 9.4. Suspended

10. Competitive Landscape

  • 10.1. Allergan Inc. (MAP Pharmaceuticals)
  • 10.2. AstraZeneca (Pearl Therapeutics)
  • 10.3. Bayer HealthCare Pharmaceuticals
  • 10.4. Boehringer Ingelheim
  • 10.5. Gilead Sciences
  • 10.6. Merck & Co
  • 10.7. Teva Pharmaceutical (Microdose Therapeutx)
  • 10.8. Novartis
  • 10.9. Pfizer
  • 10.10. Vectura Group

List of Figures

  • Figure 1-1: Drug Delivery Methods
  • Figure 1-2: Evolution Timeline of Pulmonary Drug Delivery Method
  • Figure 2-1: Segments of Pulmonary Drug Delivery System
  • Figure 4-1: Global Pulmonary Drug Delivery Market (US$ Billion), 2013-2018
  • Figure 4-2: Market Segmentation of Pulmonary Drug Delivery
  • Figure 4-3: Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-4: Number of Pulmonary Drugs in Clinical Trial by Phase, 2014
  • Figure 4-5: No Development Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-6: No Development Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-7: Discontinued Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-8: Discontinued Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-9: Suspended Pulmonary Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-10: Suspended Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Back to Top